A health insurer that runs government-sponsored plans, Centene covers tens of millions of people through Medicaid, Medicare, and its Ambetter Health marketplace plans, alongside specialty services like the AcariaHealth pharmacy. It began in 1984 when a former hospital bookkeeper, Elizabeth "Betty" Brinn, started a small nonprofit Medicaid plan in Milwaukee called Family Hospital Physician Associates. The company adopted the name "Centene" in 1997 from the Latin for "hundred," and its founding proceeds later helped create a children's foundation in Milwaukee.
Centene CFO Andrew Asher to retire; Christopher Neczypor named successor effective Jan 1, 2027
Andrew Asher will step down as CFO on December 31, 2026, then serve as Strategic Advisor through end of 2027.
Show detailsHide details
Christopher Neczypor, former Lincoln National CFO, will join Centene as EVP around September 1, 2026, and become CFO on January 1, 2027.
Neczypor's employment agreement includes $1.1M base salary, 150% target bonus, $5.25M equity award in 2027, and $10M make-whole RSUs plus $2M cash sign-on bonus.
Centene reaffirmed its 2026 adjusted diluted EPS guidance of greater than $4.80.
The transition is intended to ensure an orderly handover, with Asher supporting strategic initiatives until retirement.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Centene to redeem $500M of 4.25% Notes due 2027 on August 13, 2026
On July 29, 2026, Centene Corporation delivered a notice of partial redemption for $500,000,000 aggregate principal amount of its 4.25% Notes due December 15, 2027.
Show detailsHide details
The redemption date is August 13, 2026, and the redemption price equals 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
After the redemption, approximately $568,664,000 of the 2027 Notes will remain outstanding.
The redemption is made under the Indenture dated December 6, 2019 between Centene and The Bank of New York Mellon Trust Company, N.A. as trustee.
The filing was made under Item 8.01 (Other Events) and does not constitute a notice of redemption itself.
Centene director Kenneth Burdick resigns; Paul Diaz elected to board effective July 28, 2026
Paul Diaz was elected to the board to fill the vacancy, with a term expiring at the 2027 annual meeting.
Show detailsHide details
Kenneth Burdick resigned from Centene's Board of Directors, effective July 28, 2026, not due to any disagreement with the company.
Diaz will serve on the Audit Committee and the Quality and Compliance Committee.
Diaz is a Managing Partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare.
Diaz will participate in the standard non-employee director compensation program.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Centene expands board to 10, elects Lauren Tyler as director effective June 19, 2026
Tyler's term expires at the 2027 annual meeting; she is expected to join the Audit and Compensation and Talent Committees on July 1, 2026.
Show detailsHide details
Centene Corporation increased its Board size from 9 to 10 and elected Lauren Tyler to fill the vacancy, effective June 19, 2026.
Tyler spent over two decades at JPMorgan Chase, most recently as EVP and Global Head of HR for Asset & Wealth Management (2015-2024).
She currently serves on the boards of Cencora, Inc. and Guardian Life, and holds an MBA from Harvard Business School.
Tyler will participate in Centene's standard non-employee director compensation program; no related-party transactions or family relationships were disclosed.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Centene holds 2026 annual meeting, elects nine directors and ratifies KPMG as auditor.
At the May 12, 2026 annual meeting, all nine director nominees were elected for one-year terms, with Sarah M. London receiving the most 'for' votes (379,273,463).
Show detailsHide details
A non-binding advisory vote on executive compensation was approved, with 349,896,589 votes for and 31,993,126 against.
The appointment of KPMG LLP as independent auditor for fiscal year 2026 was ratified (390,477,647 for, 22,337,787 against).
A shareholder proposal for an independent board chairman was not approved (72,839,667 for, 308,562,931 against).
The board confirmed the executive officer list, including Sarah London as CEO, Drew Asher as CFO, and Daniel Finke and Michael Carson as Group Presidents.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
Centene appoints Theodore Pienkos as Corporate Controller and Chief Accounting Officer, effective March 18, 2026.
Pienkos previously served as Deputy Corporate Controller since August 2024 and held other accounting roles at Centene since March 2011.
Show detailsHide details
Theodore Pienkos, 44, a registered CPA, was appointed Corporate Controller and Chief Accounting Officer effective March 18, 2026.
His compensation includes a base salary of $440,000 and a target bonus of 60% of base salary, plus participation in incentive programs and executive severance plan.
Kate Casso, the prior Corporate Controller and Chief Accounting Officer since April 2021, was appointed Senior Vice President, Finance Operations and Innovation, effective March 18, 2026.
No family relationships or related party transactions were reported involving Pienkos and the company's directors or officers.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Centene to redeem $1B of 4.25% 2027 Notes and reaffirm 2026 EPS guidance
Centene Corporation will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 8:30 a.m. EDT.
Show detailsHide details
The company expects to reaffirm 2026 full-year GAAP diluted EPS guidance of greater than $1.98 and adjusted diluted EPS guidance of greater than $3.00.
On March 10, 2026, Centene delivered a notice to redeem $1,000,000,000 aggregate principal amount of its 4.25% Notes due December 15, 2027, on March 25, 2026.
The redemption price is 100% of principal plus accrued and unpaid interest to the redemption date; approximately $1,186,664,000 of the 2027 Notes will remain outstanding after redemption.
The redemption is made under the Indenture dated December 6, 2019, with The Bank of New York Mellon Trust Company, N.A. as trustee.